

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex
HPTN 046: NVP Breastfeed-Moms

	Age						Total
	Unknown or Not Reported	18-24		25+			
		Female	Female	Female	Female		
Site	#	%	#	%	#	%	Total
South Africa, Durban	0	0	175	42.9	233	57.1	408
Tanzania, Dar es Salaam	1	0.5	48	22.0	169	77.5	218
Uganda, Kampala	0	0	253	34.4	482	65.6	735
Zimbabwe, Harare/Chitungwiza	0	0	231	34.8	433	65.2	664
ALL SITES	1	0.0	707	34.9	1317	65.0	2025

HPTN Adolescence Working Group
Age at Enrollment by Site and Sex
HPTN 052: ART in HIV Serodiscordant Couples

Site	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
	#	%	#	%	#	%	#	%	
Botswana: Gabarone	16	10.3	5	3.2	62	39.7	73	46.8	156
Brazil: Porto Alegre	11	6.0	9	4.9	72	39.1	92	50.0	184
Brazil: Rio de Janeiro	29	40.9	24	13.4	142	99.4	189	146.3	384
India: Chennai	51	10.2	6	1.2	199	39.8	244	48.8	500
India: Pune	43	37.1	10	8.7	132	112.9	165	141.3	350
Kenya: Kisumu	20	16.7	3	2.5	40	33.3	57	47.5	120
Malawi: Blantyre	46	9.5	14	2.9	195	40.4	228	47.2	483
Malawi: Lilongwe	69	14.1	23	4.7	173	35.5	223	45.7	488
South Africa: Johannesburg	7	7.5	2	2.2	40	43.0	44	47.3	93
South Africa: Soweto	8	7.9	2	2.0	42	41.6	49	48.5	101
Thailand: Chiang Mai	13	6.1	9	4.2	87	40.8	104	48.8	213
United States: Boston	0	0	0	0	1	25.0	3	75.0	4
Zimbabwe: Harare	47	9.8	14	2.9	192	40.0	227	47.3	480
ALL SITES	360	10.1	121	3.4	1377	38.7	1698	47.8	3556

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex
HPTN 057: Ph I Tenofovir Mothers

	Age				Total
	18-24		25+		
	Female		Female		
Site	#	%	#	%	Total
Brazil, Belo Horizonte	3	25.0	9	75.0	12
Brazil, P Alegre: Conceicao	3	30.0	7	70.0	10
Brazil, P Alegre: Santa Casa	5	33.3	10	66.7	15
Brazil, Rio de Janeiro	5	38.5	8	61.5	13
Malawi, Blantyre	14	19.4	58	80.6	72
ALL SITES	30	24.6	92	75.4	122

HPTN Adolescence Working Group
Age at Enrollment by Site and Sex
HPTN 058: Buprenorphine/Naloxone for IDU

	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
Site	#	%	#	%	#	%	#	%	
China: Heng County	0	0	99	24.1	20	4.9	292	71.0	411
China: Nanning	0	0	0	0	17	10.6	144	89.4	161
China: Xinjiang	4	0.8	50	10.5	46	9.6	378	79.1	478
Thailand: Chiang Mai	1	0.5	12	5.9	12	5.9	177	87.6	202
ALL SITES	5	0.4	161	12.9	95	7.6	991	79.2	1252

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 061: Feasibility Study of a Community-level Intervention for Black MSM

	Age				Total
	18-24		25+		
	Male		Male		
Site	#	%	#	%	
California: Los Angeles	65	23.0	218	77.0	283
California: San Francisco	23	11.3	181	88.7	204
Georgia: Atlanta	17	15.6	92	84.4	109
Georgia: Decatur	34	18.6	149	81.4	183
Massachusetts: Boston	40	16.9	197	83.1	237
New York: Harlem	28	18.2	126	81.8	154
New York: NYBC	30	19.2	126	80.8	156
Washington, DC	79	34.8	148	65.2	227
ALL SITES	316	20.3	1237	79.7	1553

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 062: Behavioral Intervention for Individuals with Acute and Early HIV Infection

	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
Site	#	%	#	%	#	%	#	%	
Lilongwe, Malawi	5	17.9	3	10.7	4	14.3	16	57.1	28
ALL SITES	5	17.9	3	10.7	4	14.3	16	57.1	28

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 063: Preparing for International Trials Involving HIV-Infected Individuals in Care Settings

Site	Age																			Total
	Unknown or Not Reported						18-24						25+							
	Female		Male		other		Female		Male		other		Female		Male		other			
#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	
Brazil: Manguinhos	0	0	0	0	0	0	5	1.9	15	5.7	0	0	97	36.7	145	54.9	2	0.8	264	
Thailand: Chiang Mai	0	0	0	0	0	0	4	1.3	1	0.3	6	2.0	99	33.0	119	39.7	71	23.7	300	
Zambia: Lusaka	0	0	2	1.1	0	0	3	1.6	1	0.5	0	0	97	51.9	84	44.9	0	0	187	
ALL SITES	0	0	2	0.3	0	0	12	1.6	17	2.3	6	0.8	293	39.0	348	46.3	73	9.7	751	

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex
HPTN 064: ISIS

Site	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
#	%	#	%	#	%	#	%		
Atlanta	70	32.9	0	0	143	67.1	0	0	213
Baltimore	40	18.9	0	0	172	81.1	0	0	212
Bronx Lebanon	77	29.3	14	5.3	132	50.2	40	15.2	263
Chapel Hill	82	38.7	0	0	130	61.3	0	0	212
Decatur	94	36.4	19	7.4	117	45.3	28	10.9	258
Harlem	84	39.8	0	0	127	60.2	0	0	211
Newark	92	21.9	0	0	328	78.1	0	0	420
Raleigh	74	30.2	16	6.5	134	54.7	21	8.6	245
Washington DC	64	25.5	9	3.6	147	58.6	31	12.4	251
ALL SITES	677	29.6	58	2.5	1430	62.6	120	5.3	2285

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex
HPTN 066: Truvada iPrEP-PK Study

	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
Site	#	%	#	%	#	%	#	%	
Johns Hopkins Univ, Baltimore	2	6.5	2	6.5	14	45.2	13	41.9	31
UNC, Chapel Hill NC	7	36.8	2	10.5	6	31.6	4	21.1	19
ALL SITES	9	18.0	4	8.0	20	40.0	17	34.0	50

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex
HPTN 067: Intermittent PrEP Study

	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
Site	#	%	#	%	#	%	#	%	
South Africa: Cape Town	85	44.5	0	0	106	55.5	0	0	191
Thailand: Bangkok	0	0	31	16.1	0	0	162	83.9	193
US: Harlem	0	0	76	31.9	0	0	162	68.1	238
ALL SITES	85	13.7	107	17.2	106	17.0	324	52.1	622

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 068: Effects of Cash Transfer for the Prevention of HIV in Young South African Women

	Age						Total
	0-12		13-17		18-24		
	Female		Female		Female		
Site	#	%	#	%	#	%	Total
Agincourt South Africa	2	0.1	2232	88.0	303	11.9	2537
ALL SITES	2	0.1	2232	88.0	303	11.9	2537

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex
HPTN 069: NEXT-PREP: Novel Exploration of Therapeutics for PREP

Site	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
	#	%	#	%	#	%	#	%	
Baltimore, MD: JHU Adult CRS	1	3.2	3	9.7	7	22.6	20	64.5	31
Boston, MA: Fenway Institute	4	6.3	11	17.2	11	17.2	38	59.4	64
Chapel Hill, NC: UNC AIDS/Wake	4	8.0	13	26.0	17	34.0	16	32.0	50
Cleveland, OH: Case CRS	4	8.0	8	16.0	14	28.0	24	48.0	50
Los Angeles, CA: UCLA Care Cen	0	0	3	8.3	5	13.9	28	77.8	36
New Jersey Medical School CRS	1	3.1	0	0	31	96.9	0	0	32
New York City	1	2.1	4	8.5	15	31.9	27	57.4	47
Philadelphia, PA: HUP CRS	0	0	8	17.0	15	31.9	24	51.1	47
Pittsburgh, PA: Pitt CRS	5	12.5	4	10.0	10	25.0	21	52.5	40
San Francisco, CA: Vac and Pre	0	0	8	15.4	0	0	44	84.6	52
San Juan, PR: Univ of PR	1	2.7	6	16.2	14	37.8	16	43.2	37
Seattle, WA: UW AIDS CRS	1	2.9	1	2.9	7	20.0	26	74.3	35
Wake County Health and Human S	0	0	1	20.0	0	0	4	80.0	5
Washington DC: GWU CRS	8	11.8	31	45.6	12	17.6	17	25.0	68
ALL SITES	30	5.1	101	17.0	158	26.6	305	51.3	594

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex
HPTN 071: PopART

Site	Age																		Total
	Unknown or Not Reported						16-24						25+						
	Female		Male		Unknown		Female		Male		Unknown		Female		Male		Unknown		
#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Bloekombos	2	0.1	0	0	95	3.6	562	21.2	251	9.5	0	0	1294	48.9	442	16.7	0	0	2646
Chawama	1	0.0	0	0	6	0.2	907	32.9	393	14.3	0	0	1118	40.6	331	12.0	0	0	2756
Chifubu	1	0.0	0	0	0	0	920	34.2	425	15.8	0	0	1037	38.6	307	11.4	0	0	2690
Chimwemwe	0	0	0	0	3	0.2	492	26.0	281	14.9	0	0	806	42.7	307	16.3	0	0	1889
Chipata	0	0	0	0	3	0.1	870	34.9	331	13.3	0	0	986	39.6	303	12.2	0	0	2493
Chipulukusu	0	0	0	0	0	0	992	37.2	285	10.7	0	0	1117	41.9	271	10.2	0	0	2665
Cloetesville	0	0	0	0	32	1.9	364	21.5	328	19.3	0	0	600	35.4	372	21.9	0	0	1696
Dalevale	0	0	0	0	9	0.5	480	24.3	268	13.5	0	0	847	42.8	375	18.9	0	0	1979
Dambwa	0	0	0	0	1	0.0	853	30.6	357	12.8	0	0	1089	39.1	488	17.5	0	0	2788
Delft South	0	0	0	0	41	1.7	524	21.2	285	11.6	0	0	1091	44.2	526	21.3	0	0	2467
Ikhwezi	0	0	0	0	11	0.4	641	23.1	313	11.3	0	0	1278	46.0	535	19.3	0	0	2778
Kanyama	0	0	0	0	6	0.3	697	35.5	230	11.7	0	0	816	41.5	216	11.0	0	0	1965
Kuyasa	0	0	0	0	28	1.1	502	19.6	249	9.7	0	0	1339	52.4	439	17.2	0	0	2557
Luvuyo	1	0.0	0	0	58	2.3	519	20.7	293	11.7	0	0	1161	46.2	479	19.1	0	0	2511
Makululu	1	0.0	0	0	2	0.1	788	32.3	309	12.7	0	0	1001	41.0	340	13.9	0	0	2441
Maramba	0	0	0	0	2	0.1	635	31.4	271	13.4	0	0	809	40.0	305	15.1	0	0	2022
Ndeke	0	0	1	0.1	1	0.1	433	26.4	240	14.6	0	0	731	44.5	236	14.4	0	0	1642
Ngungu	0	0	0	0	0	0	540	26.2	381	18.5	0	0	850	41.2	291	14.1	0	0	2062
Shampande	0	0	1	0.0	0	0	525	24.9	290	13.8	0	0	916	43.4	377	17.9	0	0	2109
Town II	0	0	0	0	9	0.4	530	23.9	259	11.7	0	0	1035	46.7	385	17.4	0	0	2218
Wellington	0	0	0	0	46	2.2	457	21.8	268	12.8	0	0	936	44.6	389	18.6	1	0.0	2097
ALL SITES	6	0.0	2	0.0	353	0.7	1323 1	27.3	6307	13.0	0	0	2085 7	43.0	7714	15.9	1	0.0	48471

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 073: PrEP Initiation and Adherence among BSM in Three U.S. Cities

	Age				Total
	18-24		25+		
	Male		Male		
	#	%	#	%	
Site	#	%	#	%	Total
US, Chapel Hill: UNC AIDS	33	45.8	39	54.2	72
US, Los Angeles: UCLA Vine Str	24	30.8	54	69.2	78
US, Raleigh: Wake County Healt	1	33.3	2	66.7	3
US, Washington DC: George Wash	34	46.6	39	53.4	73
ALL SITES	92	40.7	134	59.3	226

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 074: Integrated Treatment and Prevention for people who Inject Drugs

	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
Site	#	%	#	%	#	%	#	%	
Indonesia	5	1.6	38	12.5	23	7.6	238	78.3	304
Ukraine	7	1.4	5	1.0	120	23.6	377	74.1	509
Vietnam	0	0	30	6.0	9	1.8	462	92.2	501
ALL SITES	12	0.9	73	5.6	152	11.6	1077	82.0	1314

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 075: Feasibility of HIV Prevention Cohort Studies among MSM in Sub-Saharan Africa

Site	Age				Total
	18-24		25+		
	Male		Male		
	#	%	#	%	
Kenya, Kisumu: KEMRI/CDC CRS	64	64.0	36	36.0	100
Malawi, Blantyre: College of M	52	52.0	48	48.0	100
South Africa, Cape Town: Univ	68	68.0	32	32.0	100
South Africa, Johannesburg: So	69	68.3	32	31.7	101
ALL SITES	253	63.1	148	36.9	401

HPTN Adolescence Working Group
Age at Enrollment by Site and Sex
HPTN 076: Phase II Safety of TMC278 LA for PrEP

	Age				Total
	18-24		25+		
	Female		Female		
Site	#	%	#	%	
South Africa, Cape Town: Emavu	21	43.8	27	56.3	48
US, New York: Bronx Prevention	3	15.8	16	84.2	19
US, Newark: New Jersey Medical	1	5.9	16	94.1	17
Zimbabwe, Harare: Spilhaus	6	11.5	46	88.5	52
ALL SITES	31	22.8	105	77.2	136

HPTN Adolescence Working Group
Age at Enrollment by Site and Sex
HPTN 077: Phase IIa Safety of GSK1265744

	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
Site	#	%	#	%	#	%	#	%	
Brazil, Rio de Janeiro: IPEC-F	7	20.6	3	8.8	17	50.0	7	20.6	34
Malawi, Lilongwe: UNC Global P	2	11.1	0	0	13	72.2	3	16.7	18
South Africa, Soweto: Soweto C	10	55.6	1	5.6	3	16.7	4	22.2	18
South Africa, Vulindlela CRS	12	50.0	0	0	12	50.0	0	0	24
US, Chapel Hill: UNC AIDS CTU	8	19.0	2	4.8	23	54.8	9	21.4	42
US, Los Angeles: UCLA Care Cen	0	0	0	0	5	27.8	13	72.2	18
US, San Francisco: Department	4	17.4	1	4.3	8	34.8	10	43.5	23
US, Washington DC: George Wash	1	4.3	1	4.3	8	34.8	13	56.5	23
ALL SITES	44	22.0	8	4.0	89	44.5	59	29.5	200

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 081: Phase 2b study to evaluate efficacy of VRC01, AMP - African women

	Age						Total
	18-24		25+		not categorized		
	Female		Female		Female		
Site	#	%	#	%	#	%	
Blantyre	17	21.0	64	79.0	0	0	81
Botha's Hill	39	54.2	33	45.8	0	0	72
Cape Town	135	70.7	56	29.3	0	0	191
Chatsworth	64	52.0	59	48.0	0	0	123
eThekwini	50	54.3	42	45.7	0	0	92
Gabarone	60	40.0	90	60.0	0	0	150
Harare-Parirenyatwa	38	24.2	119	75.8	0	0	157
Harare-Seke South	62	41.6	87	58.4	0	0	149
Harare-Spilhaus	15	12.0	110	88.0	0	0	125
Johannesburg	1	11.1	8	88.9	0	0	9
Johannesburg Ward 21	28	28.0	72	72.0	0	0	100
Kisumu-KEMRI	42	51.2	40	48.8	0	0	82
Klerksdorp	8	53.3	7	46.7	0	0	15
Lilongwe	54	55.1	44	44.9	0	0	98
Mamelodi	25	39.7	38	60.3	0	0	63
Maputo-CISPOC	17	65.4	9	34.6	0	0	26
Mbeya-NIMR	11	33.3	22	66.7	0	0	33
Rustenburg	15	40.5	22	59.5	0	0	37
Soweto-Bara	76	40.4	111	59.0	1	0.5	188
Tembisa	6	33.3	12	66.7	0	0	18
Vulindlela	62	53.9	53	46.1	0	0	115
ALL SITES	825	42.9	1098	57.1	1	0.1	1924

HPTN Adolescence Working Group
Age at Enrollment by Site and Sex
HPTN 082: Uptake and adherence to daily oral PrEP

	Age						Total
	18-24		25+		not categorized		
	Female		Female		Female		
Site	#	%	#	%	#	%	
South Africa, Cape Town: Emavu	124	87.9	2	1.4	15	10.6	141
South Africa, Johannesburg: Wa	129	79.6	31	19.1	2	1.2	162
Zimbabwe, Harare: Spilhaus	138	93.2	0	0	10	6.8	148
ALL SITES	391	86.7	33	7.3	27	6.0	451

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex
HPTN 083: Phase 2b/3 safety and efficacy study of injectable Cabotegravir

Site	Age				Total
	18-24		25+		
	Male		Male		
	#	%	#	%	
Argentina - Fundacion Huesped	44	22.3	153	77.7	197
Argentina - Hospital JM Ramos Mejia	23	16.5	116	83.5	139
Atlanta - Ponce de Leon	10	25.6	29	74.4	39
Bangkok, Thailand - Silom Clinic	78	38.4	125	61.6	203
Bangkok, Thailand - TRC-ARC CRS	114	54.0	97	46.0	211
Birmingham, US - Univ of Alabama	18	30.5	41	69.5	59
Boston, US - Fenway	21	28.0	54	72.0	75
Brazil, Porto Alegre	52	24.5	160	75.5	212
Cape Town, SA - Groote Schuur HIV	88	57.9	64	42.1	152
Chiang Mai, Thailand - CMU	85	60.7	55	39.3	140
Chicago, US - UIC Project WISH	22	28.9	54	71.1	76
Chicago, US, AYAR at CORE	30	46.2	35	53.8	65
Colorado, US - Children's	28	45.2	34	54.8	62
Georgia, US - Hope Clinic, Emory	27	30.0	63	70.0	90
Hanoi, Vietnam - Yen Hoa Health Clinic	132	66.3	67	33.7	199
Iquitos, Peru - Asociacion Civil	148	83.1	30	16.9	178
Lima, Peru - Barranco CRS	68	38.4	109	61.6	177
Lima, Peru - CITBM CRS	107	72.3	41	27.7	148
Lima, Peru - San Miguel CRS	72	47.4	80	52.6	152
Lima, Peru - Via Libre CRS	96	54.5	80	45.5	176
Los Angeles, US - UCLA CARE Center	13	19.7	53	80.3	66
Los Angeles, US - UCLA Vine St. Clinic	21	27.6	55	72.4	76
Louisiana, US - New Orleans	27	50.9	26	49.1	53
Maryland, US - Johns Hopkins	7	23.3	23	76.7	30
Memphis, US - St. Jude	82	94.3	5	5.7	87
New Jersey, US - New Jersey	20	29.9	47	70.1	67
New York, US - Bronx, Columbia	17	26.2	48	73.8	65
New York, US - Harlem Prevention Center	18	29.0	44	71.0	62
New York, US - N.Y. Blood Center CRS	14	20.3	55	79.7	69
New York, US - Weill Cornell Chelsea	13	17.6	61	82.4	74
North Carolina, US - Chapel Hill	18	27.3	48	72.7	66
North Carolina, US - Greenboro	15	26.8	41	73.2	56
Oakland - EBAC	14	34.1	27	65.9	41

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 083: Phase 2b/3 safety and efficacy study of injectable Cabotegravir

	Age				Total
	18-24		25+		
	Male		Male		
Site	#	%	#	%	Total
Ohio, US - Cincinnati CRS	21	29.2	51	70.8	72
Ohio, US - Ohio State University CRS	18	34.0	35	66.0	53
Philadelphia, US - Penn Prevention CRS	32	41.0	46	59.0	78
Rio, Brazil - IPEC CRS	113	47.3	126	52.7	239
San Francisco, US - Bridge HIV CRS	4	13.3	26	86.7	30
Sao Paulo, Brazil - CRT - DST/AIDS	38	24.1	120	75.9	158
Sao Paulo, Brazil - U. of Sao Paolo	42	22.1	148	77.9	190
St. Louis, US - Washington University	12	19.0	51	81.0	63
Texas, US - Houston AIDS Research CRS	11	17.2	53	82.8	64
Washington DC, US - George Washington	13	21.3	48	78.7	61
ALL SITES	1846	40.4	2724	59.6	4570

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir

Site	Age				Total
	18-24		25+		
	Female		Female		
	#	%	#	%	
Baylor-Uganda	77	36.7	133	63.3	210
Blantyre	23	20.5	89	79.5	112
Cape Town-Emavundleni	190	83.7	37	16.3	227
Chitungwiza-Seke South	61	38.1	99	61.9	160
Desmond Tutu TB Cent	113	71.1	46	28.9	159
Durban-Botha's Hill	123	55.2	100	44.8	223
Durban-Isipingo	114	67.1	56	32.9	170
Durban-Verulam	75	49.7	76	50.3	151
Gabarone	27	29.7	64	70.3	91
Harare-Parirenyatwa	30	19.6	123	80.4	153
Harare-Spilhaus	65	48.9	68	51.1	133
Johannesburg-Ward 21	128	61.0	82	39.0	210
Kisumu	16	24.2	50	75.8	66
Lilongwe	72	64.9	39	35.1	111
Makaerere Kampala Uganda	78	38.2	126	61.8	204
Saint Mary's Clinic (Chitungwiza)	63	38.0	103	62.0	166
Soweto HPTN CRS	98	56.0	77	44.0	175
Swaziland Prevention	83	51.9	77	48.1	160
UVRI-IAVI	102	56.0	80	44.0	182
Zengeza Clinic Chitungwiza Zimbabwe	49	30.4	112	69.6	161
ALL SITES	1587	49.2	1637	50.8	3224

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex
HPTN 085: Phase 2b study to evaluate efficacy of VRC01, AMP - MSM + TG

Site	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
	#	%	#	%	#	%	#	%	
Atlanta - Emory University	0	0	17	22.1	0	0	60	77.9	77
Atlanta - Ponce de Leon	0	0	11	21.2	0	0	41	78.8	52
Birmingham - Univ of Alabama	0	0	20	25.3	0	0	59	74.7	79
Boston - Brigham and Women's	1	1.4	24	32.4	3	4.1	46	62.2	74
Boston - Fenway Health	0	0	13	17.8	0	0	60	82.2	73
Chapel Hill	1	1.4	18	25.7	1	1.4	50	71.4	70
Cleveland	0	0	11	14.3	0	0	66	85.7	77
Columbia - Bronx Prevention	0	0	15	26.8	1	1.8	40	71.4	56
Columbia - Harlem Prevention	0	0	21	30.4	0	0	48	69.6	69
George Washington University	0	0	7	14.0	0	0	43	86.0	50
Iquitos	0	0	114	52.1	0	0	105	47.9	219
Lausanne	0	0	7	19.4	0	0	29	80.6	36
Lima - Peru	0	0	93	36.8	0	0	160	63.2	253
Lima - San Marcos	0	0	69	47.3	0	0	77	52.7	146
Lima - San Miguel	0	0	105	40.5	2	0.8	152	58.7	259
Lima - Via Libre	0	0	108	42.5	0	0	146	57.5	254
Los Angeles - UCLA	0	0	14	18.2	0	0	63	81.8	77
Nashville	0	0	19	26.0	1	1.4	53	72.6	73
New Jersey Medical School	0	0	26	45.6	0	0	31	54.4	57
New York - Columbia University	0	0	12	12.1	2	2.0	85	85.9	99
NYBC Union Square	0	0	13	16.0	2	2.5	66	81.5	81
Philadelphia/U of Pennsylvania	0	0	41	36.3	4	3.5	68	60.2	113
Rio de Janeiro	0	0	38	25.2	0	0	113	74.8	151
Rochester	2	4.5	12	27.3	0	0	30	68.2	44
San Francisco General Hospital	0	0	17	22.4	1	1.3	58	76.3	76
UW: FHCRC	2	2.3	9	10.5	3	3.5	72	83.7	86
ALL SITES	6	0.2	854	31.6	20	0.7	1821	67.4	2701

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 078: Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States

Site	Age												Total
	18-24						25+						
	Female		Male		Other		Female		Male		Other		
	#	%	#	%	#	%	#	%	#	%	#	%	
Atlanta - Ponce de Leon	0	0	8	16.7	0	0	0	0	39	81.3	1	2.1	48
Birmingham - Univ of Alabama	0	0	2	5.9	0	0	0	0	30	88.2	2	5.9	34
Harvard - Fenway	0	0	0	0	0	0	1	3.7	25	92.6	1	3.7	27
Johns Hopkins University	0	0	3	8.6	0	0	0	0	32	91.4	0	0	35
ALL SITES	0	0	13	9.0	0	0	1	0.7	126	87.5	4	2.8	144

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HVTN 127/HPTN 087: Phase I clinical trial to evaluate the safety and serum concentrations of a human monoclonal antibody

	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
Site	#	%	#	%	#	%	#	%	
Atlanta - Ponce de leon	2	14.3	1	7.1	9	64.3	2	14.3	14
Birmingham	0	0	0	0	9	64.3	5	35.7	14
Boston - Brigham	12	36.4	9	27.3	8	24.2	4	12.1	33
Boston - Fenway	5	22.7	3	13.6	9	40.9	5	22.7	22
Chapel Hill	4	23.5	1	5.9	7	41.2	5	29.4	17
Lausanne	1	12.5	1	12.5	4	50.0	2	25.0	8
New York - Physicians & Surgeons	3	18.8	4	25.0	2	12.5	7	43.8	16
ALL SITES	27	21.8	19	15.3	48	38.7	30	24.2	124

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HVTN 130/HPTN 089: A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adult participants

	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
Site	#	%	#	%	#	%	#	%	
Boston - Fenway	1	12.5	0	0	5	62.5	2	25.0	8
Nashville	1	16.7	0	0	3	50.0	2	33.3	6
New York - Harlem Prev	0	0	1	20.0	2	40.0	2	40.0	5
New York - Physicians & Surgeons	3	37.5	0	0	1	12.5	4	50.0	8
ALL SITES	5	18.5	1	3.7	11	40.7	10	37.0	27

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 091: Integrating HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation for Transgender Women in the Americas: A Vanguard Study

Site	Age				Total
	18-24		25+		
	Male		Male		
	#	%	#	%	
Houston AIDS Research Team CRS	11	21.6	40	78.4	51
New York - Harlem Prevention	12	24.5	37	75.5	49
Philadelphia	22	44.9	27	55.1	49
Rio de Janeiro - Manguinhos	22	20.0	88	80.0	110
San Francisco	8	17.8	37	82.2	45
ALL SITES	75	24.7	229	75.3	304

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HPTN 094: INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care

Site	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
	#	%	#	%	#	%	#	%	
Houston AIDS Research Team CRS	1	1.0	0	0	34	33.0	68	66.0	103
Los Angeles - Vine Street	1	1.0	2	2.1	27	28.1	66	68.8	96
New York - Bronx Prevention	1	1.1	1	1.1	26	27.7	66	70.2	94
Philadelphia	2	1.8	1	0.9	41	36.3	69	61.1	113
Washington DC - Washington Circle	0	0	1	2.4	9	22.0	31	75.6	41
ALL SITES	5	1.1	5	1.1	137	30.6	300	67.1	447

HPTN Adolescence Working Group

Age at Enrollment by Site and Sex

HVTN 140/HPTN 101: A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants

Site	Age								Total
	18-24				25+				
	Female		Male		Female		Male		
#	%	#	%	#	%	#	%		
Atlanta - Hope Clinic	0	0	0	0	5	71.4	2	28.6	7
Cape Town - Groote Schuur	3	37.5	0	0	4	50.0	1	12.5	8
Durban - eThekweni	1	16.7	2	33.3	1	16.7	2	33.3	6
Harare - Milton Park	0	0	3	100.0	0	0	0	0	3
Harare - Seke South	0	0	2	33.3	3	50.0	1	16.7	6
Harare - Spilhaus	0	0	4	66.7	0	0	2	33.3	6
Johannesburg - Ward	0	0	0	0	9	100.0	0	0	9
Kericho - KEMRI	0	0	3	33.3	2	22.2	4	44.4	9
Nashville - Vanderbilt	2	15.4	1	7.7	6	46.2	4	30.8	13
Newark	0	0	0	0	0	0	1	100.0	1
San Francisco	2	25.0	1	12.5	2	25.0	3	37.5	8
Soweto - Bara	0	0	9	90.0	0	0	1	10.0	10
Washington DC - Washington Circle	1	11.1	0	0	7	77.8	1	11.1	9
ALL SITES	9	9.5	25	26.3	39	41.1	22	23.2	95